CNS pipeline · person
David Wheadon, MD
Board member of Seaport Therapeutics. Physician and psychiatrist with 30+ years in regulatory affairs, most recently SVP of Global Regulatory Affairs at AstraZeneca. Served on the board of Karuna Therapeutics until its acquisition by Bristol Myers Squibb (2024), with earlier roles at Abbott, GlaxoSmithKline and PhRMA.
- 1 company
Courtesy Seaport Therapeutics
Current roles
- Seaport Therapeutics, Inc.Board Member · Board
Appears with
People sharing a company with David.
- Antony Loebel · Seaport Therapeutics, Inc.
- Bob Hombach · Seaport Therapeutics, Inc.
- Daphne Zohar · Seaport Therapeutics, Inc.
- Denice Torres · Seaport Therapeutics, Inc.
- Eric Green · Seaport Therapeutics, Inc.
- Jason Pitts · Seaport Therapeutics, Inc.
- Jim Healy · Seaport Therapeutics, Inc.
- Lana Gladstein · Seaport Therapeutics, Inc.
- Lauren White · Seaport Therapeutics, Inc.
- Michael Chen · Seaport Therapeutics, Inc.
- Sandi Peterson · Seaport Therapeutics, Inc.
- Sharon Mates · Seaport Therapeutics, Inc.
- Steven Paul · Seaport Therapeutics, Inc.
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.